JP Morgan Chase’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-7,712
| Closed | -$15K | – | 8114 |
|
|
2023
Q4 | $15K | Buy |
7,712
+4,243
| +122% | +$8.53K | ﹤0.01% | 6316 |
|
|
2023
Q3 | $8.36K | Buy |
3,469
+3,464
| +69,280% | +$8.52K | ﹤0.01% | 6292 |
|
|
2023
Q2 | $15 | Sell |
5
-1
| -17% | -$5 | ﹤0.01% | 6799 |
|
|
2023
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 7447 |
|
|
2022
Q4 | $0 | Buy |
+6
| New | +$70 | ﹤0.01% | 7233 |
|
|
2022
Q3 | – | Sell |
-3
| Closed | -$74 | – | 7050 |
|
|
2022
Q2 | $0 | Buy |
+3
| New | +$435 | ﹤0.01% | 7096 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 7198 |
|
|
2021
Q4 | – | Sell |
-2
| Closed | -$2.82K | – | 7131 |
|
|
2021
Q3 | $4K | Sell |
2
-65
| -97% | -$147K | ﹤0.01% | 6274 |
|
|
2021
Q2 | $179K | Sell |
67
-9
| -12% | -$29.7K | ﹤0.01% | 5301 |
|
|
2021
Q1 | $315K | Sell |
76
-9
| -11% | -$48.6K | ﹤0.01% | 4943 |
|
|
2020
Q4 | $485K | Buy |
85
+61
| +254% | +$359K | ﹤0.01% | 4384 |
|
|
2020
Q3 | $149K | Buy |
24
+5
| +26% | +$28.7K | ﹤0.01% | 4512 |
|
|
2020
Q2 | $103K | Buy |
+19
| New | +$98.7K | ﹤0.01% | 4555 |
|
|
2019
Q3 | – | Sell |
-38
| Closed | -$108K | – | 6043 |
|
|
2019
Q2 | $108K | Buy |
38
+36
| +1,800% | +$101K | ﹤0.01% | 4904 |
|
|
2019
Q1 | $5K | Buy |
+2
| New | +$4.24K | ﹤0.01% | 5619 |
|
|
2018
Q2 | – | Sell |
-66
| Closed | -$337K | – | 5749 |
|
|
2018
Q1 | $337K | Buy |
66
+4
| +6% | +$26.4K | ﹤0.01% | 4180 |
|
|
2017
Q4 | $332K | Buy |
62
+6
| +11% | +$55.9K | ﹤0.01% | 4250 |
|
|
2017
Q3 | $467K | Buy |
+56
| New | +$430K | ﹤0.01% | 3855 |
|
|
2017
Q2 | – | Sell |
-4
| Closed | -$27K | – | 5310 |
|
|
2017
Q1 | $27K | Sell |
4
-5
| -56% | -$25.1K | ﹤0.01% | 4669 |
|
|
2016
Q4 | $106K | Buy |
+9
| New | +$126K | ﹤0.01% | 4382 |
|
|
2016
Q3 | – | Sell |
-3
| Closed | -$46K | – | 4897 |
|
|
2016
Q2 | $46K | Buy |
+3
| New | +$41.1K | ﹤0.01% | 4067 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4346 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4630 |
|
Other funds holding AGRX
JP Morgan Chase's AGRX Position: Q1 2024 in Review
JP Morgan Chase sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 7,712 shares — an estimated $15K sold.
JP Morgan Chase first reported a position in AGRX in Q2 2016 and held it in 20 quarters. The position peaked at $485K in Q4 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- JP Morgan Chase reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- JP Morgan Chase sold 7,712 Agile Therapeutics shares in Q1 2024, an estimated $15K.
- JP Morgan Chase first reported a position in Agile Therapeutics in Q2 2016 and held it in 20 quarters.
- JP Morgan Chase's Agile Therapeutics position peaked at $485K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.